跳至主要内容
临床试验/NCT06957223
NCT06957223已完成不适用

Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial

Asad Ullah Jan4 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年5月6日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80
试验地点
4
主要终点
Change in Depression Severity (measured by HAMD-17)

研究概览

简要总结

The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with major depressive disorder (MDD) per DSM-5 criteria.
  • Baseline depression score indicating moderate to severe depression
  • Ability to provide informed consent
  • Willing to comply with study requirements

排除标准

  • History of bipolar disorder, schizophrenia, or other psychotic disorders
  • Current substance use disorder (within past 6 months)
  • Active suicidal ideation requiring urgent intervention
  • Pregnancy or breastfeeding
  • Known hypersensitivity to study medications

研究组 & 干预措施

SSRI Group

Active Comparator

Participants will receive an SSRI at standard therapeutic doses, administered orally for 6 weeks.

干预措施: SSRIs (Drug)

Dextromethorphan-Bupropion Group

Experimental

Participants will receive a fixed-dose combination of dextromethorphan-bupropion, dosed according to approved guidelines for major depressive disorder, administered orally for 6 weeks.

干预措施: Dextromethorphan-Bupropion (Drug)

结局指标

主要结局

Change in Depression Severity (measured by HAMD-17)

时间窗: 6 weeks

Change from baseline in depressive symptom scores, measured using the Hamilton Depression Rating Scale, 17-item version (HAMD-17; score range 0-52, with higher scores indicating worse depression severity).

次要结局

  • Remission Rate(6 weeks)

研究者

发起方
Asad Ullah Jan
申办方类型
Other Gov
责任方
Sponsor Investigator
主要研究者

Asad Ullah Jan

Head Department of Psychiatry

Combined Military Hospital Nowshera

研究点 (4)

Loading locations...

相似试验

Efficacy of Dextromethorphan-Bupropion Versus SSRIs... | 临床试验